Tag: Boston Scientific
ACURATE IDE results put spotlight on impact of valve under-expansion after TAVI
“Disappointed is an understatement,” Michael Reardon (Houston Methodist DeBakey Heart & Vasc...
Medtech Insights: Trial pipeline underpins growth strategy for Watchman LAAC device
Investment in a programme of clinical trials will underpin Boston Scientific’s strategy to expand th...
REAL-PE demonstrates statistically significant lower major bleeding rates with Ekos system compared to mechanical thrombectomy for PE treatment
Data from the REAL-PE study, presented at TCT 2023 (23–26 October, San Francisco, USA) demonstra...
Boston Scientific announces position on FDA update about use of paclitaxel-coated devices to treat PAD
Following yesterday's news that the US Food and Drug Administration (FDA) has changed its stance on ...
ADVERTORIAL: Keeping stroke at bay for patients undergoing TAVI
This advertorial is sponsored by Boston Scientific
Stroke—particularly disabling stroke—is among ...
ADVERTORIAL: “No stroke is innocent”: Why stroke matters for TAVI patients
This advertorial is sponsored by Boston Scientific
Today there are more than 75,000 transcatheter...
Boston Scientific closes acquisition of Baylis Medical Company
Boston Scientific has announced the close of its acquisition of Baylis Medical Company, a compan...
Next-generation Watchman LAAC device gains US FDA approval
Boston Scientific has received US Food and Drug Administration (FDA) approval for the Watchman F...
Boston Scientific reveals CE mark for Acurate neo 2 in Q1 financial results report
Boston Scientific, according to a press release announcing the company’s Q1 2020 financial resul...
ACURATE neo helps facilitate early discharge following TAVI procedures
NOTE: This video is ONLY available to watch in selected countries and geographies
Rajesh ...
Selecting the right valve for the patient is key for a successful TAVI program
NOTE: This video is ONLY available to watch in selected countries and geographies
Azeem Latib ...
Boston Scientific announces schedule of presentations at TCT 2019
Boston Scientific has announced the key data that will be presented at the Transcatheter Cardiov...
Novel repositionable TAVI valve has acceptable early clinical outcomes
A new study indicates that the Meridian transcatheter aortic valve implantation (TAVI) valve (HL...
New trial to compare Watchman FLX to direct oral anticoagulants
The OPTION trial is to compare the compare safety and effectiveness of the next-generation Watch...
Boston Scientific initiates trial comparing left atrial appendage closure to direct oral anticoagulants for stroke risk reduction post-AFib ablation
According to a press release, Boston Scientific has initiated the OPTION trial to compare safety...
Lotus Edge becomes third TAVI device on US market
Boston Scientific has received US FDA approval for its Lotus Edge transcatheter aortic valve imp...
CE mark for Watchman FLX left atrial appendage closure device
Boston Scientific announced it has received CE mark and initiated a limited market release of the ne...
Boston Scientific, Edwards Lifesciences agree to global litigation settlement
Boston Scientific and Edwards Lifesciences today announced that the companies have reached an agreem...
Boston Scientific exercises option to acquire Millipede
Boston Scientific has exercised its option to acquire the remaining shares of Millipede, upon it...
US District Court for the District of Delaware rules that Sapien 3 infringes a Boston Scientific patent
A jury in the US District Court for the District of Delaware determined that the Boston Scientif...
ADVERTORIAL: Unique design and features of the ACURATE neo (TM) enable safe and efficient procedures
This content is only for readers outside of the US as it discusses a device that is not FDA appr...
PCR LV 2018: Favourable outcomes for next-generation Acurate neo2 TAVI system
A new study evaluating the safety and performance of the Acurate neo2 (Boston Scientific) transc...
Boston Scientific to buy cerebral protection system company
Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commerciali...
EuroPCR 2018: Boston Scientific outlines its key presentations
Boston Scientific Corporation has revealed its schedule of key presentations—including two late-...
Boston Scientific successfully opposes Edwards Lifesciences Corporation’s European patent EP 2,399,550 (550)
According to a press release, Boston Scientific has, along with several other opponents, success...
UK Court of Appeal dismisses Edwards Lifesciences’ appeal against Sapien 3 infringement ruling
Acurate neo
Boston Scientific has announced the UK Court of Appeal dismissed Edwards Lifesc...
Short-term DAPT is feasible for patients undergoing percutaneous LAA closure
Felix Weise (Cardioangiologisches Centrum Bethanien, Frankfurt, Germany) and others report in Eu...
Boston Scientific enters into an acquisition option agreement with Millipede
Boston Scientific has closed an investment and entered into an acquisition option agreement with...
Boston Scientific pushes back plans for commercialisation of Lotus Edge TAVI device
Boston Scientific has announced a delay to the previously communicated timelines for the commerc...
TCT 2017: Vivek Reddy on the final outcomes of PREVAIL and PROTECT-AF
Boston Scientific has announced the final five-year outcomes data from the PREVAIL study during ...
TCT 2017: No role for bare metal stents to reduce duration of dual antiplatelet therapy in older patients
Olivier Varenne (Hôpital Cochin, Assistance Publique—Hôpitaux De Paris, Paris, France) reported ...
TCT 2017: Boston Scientific reveals presentations at conference
Boston Scientific has announced key data will be presented at next week’s Transcatheter Cardiova...
PCR LV 2017: Refining implantation technique and device iterations may improve pacemaker rate seen with Lotus
New data from REPRISE III indicate that keeping the bottom of the frame at annular level while i...
ESC 2017: Best-practice PCI outperforms conventional PCI in patients with de novo three-vessel disease
The SYNTAX II study has found that percutaneous coronary intervention (PCI) using state-of-the-a...
EuroPCR 2017: Lotus TAVI device has superior efficacy to CoreValve at one year
Data from the REPRISE III trial indicate that the Lotus transcatheter aortic valve implantation (TAV...
SCAI 2017: New data from PLATINUM Diversity study provide further insight into under-served populations
New analyses from the PLATINUM Diversity study underscore the need for greater understanding of ...
Boston Scientific closes Symetis acquisition
Boston Scientific Corporation has announced the close of its acquisition of Symetis SA, a privat...
ADVERT: SYNERGY™
Everolimus-Eluting Platinum Chromium Coronary Stent System
Drug Eluting stent technology with...
UK Patents Court makes initial decision on Edwards Sapien 3 and Boston Scientific’s patents
The Patents Court in the UK has determined that one of Boston Scientific’s patents related to ou...
Corindus Vascular Robotics announces private placement for US$45 million
Corindus Vascular Robotics has entered into a Securities Purchase Agreement pursuant to which it...
Locking mechanism problems prompt Boston Scientific to recall all ranges of its Louts TAVI device
According to Reuters, Boston Scientific is recalling all ranges of its transcatheter aortic valv...
Boston Scientific closes acquisition of certain Neovasc assets
Boston Scientific Corporation has closed its acquisition of certain manufacturing assets and cap...
Boston Scientific to acquire Neovasc biological tissue capabilities
Boston Scientific has agreed to acquire certain manufacturing assets and capabilities of the Neo...
TCT 2016: Women and minorities have a significantly higher risk of death after PCI than white men
Data from the PLATINUM DIVERSITY trial, which was presented at the 2016 Transcatheter Cardiovasc...
TCT 2016: Boston Scientific announces scheduled presentations
Boston Scientific has announced key data that will be presented at the 2016 Transcatheter Cardio...
Ian Meredith to become global chief medical officer of Boston Scientific
Ian Meredith, currently professor of Medicine and Cardiology for Monash University, Director of ...
Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent
The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular ste...
PCRLV 2016: Next-generation of Lotus TAVI receives CE mark
Coinciding with PCR London Valves (18-20 September, London, UK), Boston Scientific has announced...
Boston Scientific issues urgent recall of Lotus systems manufactured prior to March 2016.
Boston Scientific has sent a letter to its customers notifying them that it is implementing a “v...
